bmt {geecure}

Bone marrow transplantation data

Description

This multi-center acute leukemia study consists of 137 patients with acute myelocytic leukemia (AML) or acute lymphoblastic leukemia (ALL) aged 7 to 52 from March 1, 1984 to June 30, 1989 at four institutions (Klein and Moeschberger, 2003). The failure time on study is defined at time (in days) to relapse or death.

Usage

data(bmt)

Format

The variables represented in the data set are as follows:

g

Disease group: 1 - All, 2 - AML Low Risk, 3 - AML High Risk.

T1

Time to death or on study time.

T2

Disease free survival time (time to relapse, death or end of study).

d1

Death indicator: 1 - Dead, 0 - Alive.

d2

Relapse indicator: 1 - Relapsed, 0 - Disease Free.

d3

Disease free survival indicator: 1 - Dead or Relapsed, 0 - Alive Disease Free.

TA

Time to Acute Graft-Versus-Host Disease.

da

Acute GVHD indicator: 1 - Developed Acute GVHD, 0 - Never Developed Acute GVHD.

TC

Time to Chronic Graft-Versus-Host Disease.

dc

Chronic GVHD Indicator: 1 - Developed Chronic GVHD, 0 - Never Developed Chronic GVHD.

TP

Time to return of platelets to normal levels.

dp

Platelet recovery indicator: 1 - platelets returned to normal, 0 - platelets never returned to normal.

Z1

Patient age in years.

Z2

Donor age in years.

Z3

Patient sex: 1 - Male, 0 - Female.

Z4

Doner sex: 1 - Male, 0 - Female.

Z5

Patient CMV status: 1 - CMV positive, 0 - CMV negative.

Z6

Donor CMV status: 1 - CMV positive, 0 - CMV negative.

Z7

Waiting time to transplant in days.

Z8

FAB: 1 - FAB Grade 4 or 5 and AML, 0 - otherwise.

Z9

Hospital: 1 - The Ohio State University, 2 - Alferd , 3 - St. Vincent, 4 - Hahnemann.

Z10

MTX: used as a Graft-Versus-Host-Prophylactic 1 - Yes, 0 - No.

References

Klein, J. P. and Moeschberger, M. L. (2003) Survival Analysis: Techniques for Censored and Truncated Data. Springer, New York, 2nd edition.